Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits

Glycosylation-dependent programs control intestinal inflammation. Diverse immunoregulatory circuits operate to preserve intestinal homeostasis and prevent inflammation. Galectin-1 (Gal1), a β-galactoside–binding protein, promotes homeostasis by reprogramming innate and adaptive immunity. Here, we identify a glycosylation-dependent “on-off” circuit driven by Gal1 and its glycosylated ligands that controls intestinal immunopathology by targeting activated CD8+ T cells and shaping the cytokine profile. In patients with inflammatory bowel disease (IBD), augmented Gal1 was associated with dysregulated expression of core 2 β6-N-acetylglucosaminyltransferase 1 (C2GNT1) and α(2,6)-sialyltransferase 1 (ST6GAL1), glycosyltransferases responsible for creating or masking Gal1 ligands. Mice lacking Gal1 exhibited exacerbated colitis and augmented mucosal CD8+ T cell activation in response to 2,4,6-trinitrobenzenesulfonic acid; this phenotype was partially ameliorated by treatment with recombinant Gal1. While C2gnt1−/− mice exhibited aggravated colitis, St6gal1−/− mice showed attenuated inflammation. These effects were associated with intrinsic T cell glycosylation. Thus, Gal1 and its glycosylated ligands act to preserve intestinal homeostasis by recalibrating T cell immunity.

[1]  M. Bauer,et al.  Intracellular immune sensing promotes inflammation via gasdermin D–driven release of a lectin alarmin , 2021, Nature Immunology.

[2]  S. Stowell,et al.  Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD , 2020, Nature Reviews Gastroenterology & Hepatology.

[3]  G. Rabinovich,et al.  Galectin-1 Facilitates Macrophage Reprogramming and Resolution of Inflammation Through IFN-β , 2020, Frontiers in Pharmacology.

[4]  K. Lassen,et al.  Gasdermin D in macrophages restrains colitis by controlling cGAS-mediated inflammation , 2020, Science Advances.

[5]  Mark B. Jones,et al.  Disruption of hepatocyte Sialylation drives a T cell-dependent pro-inflammatory immune tone , 2020, Glycoconjugate Journal.

[6]  G. Rabinovich,et al.  Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits , 2020, Proceedings of the National Academy of Sciences.

[7]  T. Spector,et al.  Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases , 2020, Science Advances.

[8]  S. Dodd,et al.  Serum galectins as potential biomarkers of inflammatory bowel diseases , 2020, PloS one.

[9]  G. Lauc,et al.  Inflammatory bowel disease - glycomics perspective. , 2019, Biochimica et biophysica acta. General subjects.

[10]  Aviv Regev,et al.  Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis , 2019, Cell.

[11]  N. Gagliani,et al.  Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification , 2019, Nature Communications.

[12]  Samuel J. S. Rubin,et al.  Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases , 2019, Nature Communications.

[13]  Judy H. Cho,et al.  Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy , 2019, Cell.

[14]  R. Cross,et al.  A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. , 2018, Inflammatory bowel diseases.

[15]  A. Kispert,et al.  Sialic acid is a critical fetal defense against maternal complement attack , 2018, The Journal of clinical investigation.

[16]  H. Tilg,et al.  IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting , 2018, Nature Reviews Gastroenterology & Hepatology.

[17]  N. Taniguchi,et al.  Metabolic control of T cell immune response through glycans in inflammatory bowel disease , 2018, Proceedings of the National Academy of Sciences.

[18]  J. Mucci,et al.  Galectin-3 deficiency drives lupus-like disease by promoting spontaneous germinal centers formation via IFN-γ , 2018, Nature Communications.

[19]  G. Rabinovich,et al.  Untangling Galectin-Driven Regulatory Circuits in Autoimmune Inflammation. , 2018, Trends in molecular medicine.

[20]  G. Rabinovich,et al.  Galectins in Intestinal Inflammation: Galectin-1 Expression Delineates Response to Treatment in Celiac Disease Patients , 2018, Front. Immunol..

[21]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[22]  V. Nizet,et al.  Recurrent infection progressively disables host protection against intestinal inflammation , 2017, Science.

[23]  G. Rabinovich,et al.  Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation , 2017, The Journal of Immunology.

[24]  T. Ritter,et al.  Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function , 2017, Front. Immunol..

[25]  G. Rabinovich,et al.  Galectin-1–Driven Tolerogenic Programs Aggravate Yersinia enterocolitica Infection by Repressing Antibacterial Immunity , 2017, The Journal of Immunology.

[26]  S. Ng,et al.  The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21 st Century: A Systematic Review of Population-Based Studies , 2017 .

[27]  Ajit Varki,et al.  Biological roles of glycans , 2016, Glycobiology.

[28]  S. Stowell,et al.  Cosmc is an X-linked inflammatory bowel disease risk gene that spatially regulates gut microbiota and contributes to sex-specific risk , 2016, Proceedings of the National Academy of Sciences.

[29]  L. Peyrin-Biroulet,et al.  Next generation of small molecules in inflammatory bowel disease , 2016, Gut.

[30]  G. Rabinovich,et al.  Inflammation Controls Sensitivity of Human and Mouse Intestinal Epithelial Cells to Galectin‐1 , 2016, Journal of cellular physiology.

[31]  G. Kaplan,et al.  Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[32]  M. Breimer,et al.  Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis , 2016, BioMed research international.

[33]  Erin Stevens,et al.  Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. , 2015, Immunity.

[34]  J. Niess,et al.  CD69 Is the Crucial Regulator of Intestinal Inflammation: A New Target Molecule for IBD Treatment? , 2015, Journal of immunology research.

[35]  J. Paulson,et al.  Siglec-mediated regulation of immune cell function in disease , 2014, Nature Reviews Immunology.

[36]  Daniel Kolarich,et al.  The role of glycosylation in IBD , 2014, Nature Reviews Gastroenterology &Hepatology.

[37]  P. Lago,et al.  Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. , 2014, Human molecular genetics.

[38]  M. Bilgin,et al.  Protective effects of citicoline on TNBS-induced experimental colitis in rats. , 2014, International journal of clinical and experimental medicine.

[39]  Gabriel A. Rabinovich,et al.  Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors , 2014, Cell.

[40]  F. Bäckhed,et al.  Altered Mucus Glycosylation in Core 1 O-Glycan-Deficient Mice Affects Microbiota Composition and Intestinal Architecture , 2014, PloS one.

[41]  J. Marth,et al.  A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins. , 2013, Glycobiology.

[42]  Arne K. Sandvik,et al.  Whole Genome Gene Expression Meta-Analysis of Inflammatory Bowel Disease Colon Mucosa Demonstrates Lack of Major Differences between Crohn's Disease and Ulcerative Colitis , 2013, PloS one.

[43]  H. Ikeuchi,et al.  Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells , 2012, The Journal of experimental medicine.

[44]  G. Rabinovich,et al.  Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. , 2012, Immunity.

[45]  V. Kuchroo,et al.  Galectin-1 Triggers an Immunoregulatory Signature in Th Cells Functionally Defined by IL-10 Expression , 2012, The Journal of Immunology.

[46]  G. Rabinovich,et al.  Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. , 2012, Immunity.

[47]  G. Rabinovich,et al.  When galectins recognize glycans: from biochemistry to physiology and back again. , 2011, Biochemistry.

[48]  J. Braun,et al.  Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. , 2011, The Journal of clinical investigation.

[49]  A. Moran,et al.  Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract , 2011, Gut.

[50]  L. Earl,et al.  N- and O-Glycans Modulate Galectin-1 Binding, CD45 Signaling, and T Cell Death* , 2009, The Journal of Biological Chemistry.

[51]  G. Rabinovich,et al.  Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 , 2009, Nature Immunology.

[52]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[53]  Jeff F. Miller,et al.  Galectin-1 Tunes TCR Binding and Signal Transduction to Regulate CD8 Burst Size1 , 2009, The Journal of Immunology.

[54]  C. Decaestecker,et al.  Expression of galectins‐1, ‐3 and ‐4 varies with strain and type of experimental colitis in mice , 2008, International journal of experimental pathology.

[55]  L. Rink,et al.  Dendritic cell subsets in lymph nodes are characterized by the specific draining area and influence the phenotype and fate of primed T cells , 2008, Immunology.

[56]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[57]  J. Correale,et al.  Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death , 2007, Nature Immunology.

[58]  G. Rabinovich,et al.  A Novel Function for Galectin-1 at the Crossroad of Innate and Adaptive Immunity: Galectin-1 Regulates Monocyte/Macrophage Physiology through a Nonapoptotic ERK-Dependent Pathway1 , 2007, The Journal of Immunology.

[59]  B. Flourié,et al.  CD8+ cytotoxic T cells induce relapsing colitis in normal mice. , 2006, Gastroenterology.

[60]  Mariano J. Alvarez,et al.  Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. , 2004, Cancer cell.

[61]  G. Rabinovich,et al.  Galectin-1 suppresses experimental colitis in mice. , 2003, Gastroenterology.

[62]  H. Buhr,et al.  Changes of Colonic Mucosal Microcirculation and Histology in Two Colitis Models: An Experimental Study Using Intravital Microscopy and a New Histological Scoring System , 2001, Digestive Diseases and Sciences.

[63]  M. Neurath,et al.  Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. , 1999, Gastroenterology.

[64]  E. Bloemena,et al.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.

[65]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[66]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[67]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[68]  Kiyoko F. Aoki-Kinoshita,et al.  Updates to the Symbol Nomenclature for Glycans guidelines , 2019 .

[69]  European Crohn’s and Colitis Organisation , 2019, The Grants Register 2022.

[70]  C. Hewitt,et al.  Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I. , 2018, Inflammatory bowel diseases.

[71]  G. Rabinovich,et al.  A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders. , 2016, BioFactors.

[72]  G. Vasta.  Galectins as pattern recognition receptors: structure, function, and evolution. , 2012, Advances in experimental medicine and biology.

[73]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.